Description of Business

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Description of Business

Note 1. Description of Business

HTG Molecular Diagnostics, Inc. (the “Company”) is a commercial stage company that develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The Company derives revenue from sales of its automation system and integrated next-generation sequencing-based HTG EdgeSeq assays and from sample processing, custom research use only assay development, and collaborative development services.

The Company operates in one segment and the majority of its customers are located in the United States and Europe. For the three and nine months ended September 30, 2017 approximately 68% and 49%, respectively, of the Company’s revenue was generated from sales to customers located outside of the United States, compared with 15% and 11%, respectively, for the three and nine months ended September 30, 2016. The increase in sales to customers located outside of the United States is primarily the result of the Master Assay Development, Commercialization and Manufacturing Agreement with QIAGEN Manchester Limited (See Note 14), which accounted for 85% and 72% of sales to customers located outside of the United States for the three and nine months ended September 30, 2017.